drugset / Trial / NCT04094506
Study of ASP1948, Targeting an Immune Modulatory Receptor, in Japanese Patients With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary purpose of this study is to evaluate the tolerability, safety and pharmacokinetic profile of ASP1948 in Japanese patients with locally advanced (unresectable) or metastatic solid tumors. This study will also evaluate the antitumor effect of ASP1948.
Timeline
- Start
- 2019-10-30
- Primary completion
- 2022-02-02
- Completion
- 2022-02-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ASP1948 | Unknown | 1200 mg | Intravenous |
| Subject | ASP1948 | Unknown | 2000 mg | Intravenous |
| Subject | ASP1948 | Unknown | 3000 mg | Intravenous |